Core Points - Vaxil Bio Ltd. announced a non-brokered private placement offering of up to 3,111,111 units at a price of $0.1125 per unit, aiming to raise gross proceeds of up to $350,000 [2][3] - Each unit consists of one common share and one share purchase warrant, with warrants allowing the purchase of additional shares at $0.15 for five years [2] - The net proceeds will be used for general corporate purposes, and the offering is expected to close around December 4, 2025, pending approval from the TSX Venture Exchange [3] Financial Details - The company will pay finders a cash commission of up to 8% of the gross proceeds and issue non-transferrable warrants equal to 8% of the total units issued [4] - The units, shares, and warrants will be subject to a hold period of four months and one day from the date of issue [4] Company Background - Vaxil is an immunotherapy biotech company focused on targeting cancer markers and infectious diseases, with its lead product being ImMucin™, which has received orphan drug status from the FDA and EMA [5] - The company is exploring other business opportunities to enhance shareholder value, which may or may not be within the biotechnology sector [5]

Contract will enable secure, high-capacity government communications across three continentsOTTAWA, Ontario, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Calian Group Ltd. (TSX: CGY), a trusted provider of mission-critical solutions for defence, space, healthcare, and other critical infrastructure sectors, today announced it has been awarded a contract by a leading global space technology company for the design and manufacturing of four Ka/Q/V-band RF gateway ground stations to support the roll-out of services for two ...

Core Insights - Cannara Biotech Inc. reported its strongest annual performance in Fiscal 2025, achieving record revenues and significant growth across key financial metrics [3][5][8] - The company increased its national market share by nearly 32% year-over-year, reaching 3.81%, with a notable 53% increase in Quebec, bringing its market share to 12.72% [3][5][20] - Cannara plans to expand its cultivation capacity by approximately 100% over the next four years through the operationalization of additional grow rooms [3][15] Financial Performance - Record net revenues of $107.3 million for Fiscal 2025, a 31% increase from $82.2 million in Fiscal 2024 [5][8] - Adjusted EBITDA rose by 86% to $28.1 million, while net income increased by 103% to $13.1 million [11][24] - Operating cash flow reached $20 million, and free cash flow was $13.7 million for the fiscal year [5][11] Operational Highlights - Gross cannabis revenue before excise taxes increased by 35% to $148.6 million, driven by market penetration and new product offerings [8][11] - The company successfully activated two additional grow zones, increasing total annual production capacity to 39,500 kilograms, achieving its Fiscal 2026 production target ahead of schedule [13][14] - Cannara's disciplined approach to expansion focuses on maintaining margins while enhancing brand recognition across its product lines [14][16] Market Share Expansion - The company’s market share in various provinces showed significant growth, with Manitoba increasing by 342% and Nova Scotia by 860% [20] - Cannara's strategic entry into Quebec's new vape cartridge category with five approved SKUs is expected to further strengthen its market position [16][20] Future Outlook - The company is prioritizing capital investments for a new processing center, supported by a $10 million term loan from BMO, with completion expected by the end of Fiscal 2026 [15][22] - Cannara plans to operationalize three additional grow zones in preparation for future cultivation expansion [15][22]

Core Viewpoint - Aquestive Therapeutics, Inc. is actively participating in the Piper Sandler 37th Annual Healthcare Conference, highlighting its commitment to advancing innovative medicines and engaging with investors [1][2]. Company Overview - Aquestive Therapeutics is a pharmaceutical company focused on improving patients' lives through innovative science and delivery technologies, developing orally administered and topical gel products to deliver complex molecules [4]. - The company has four commercialized products marketed by licensees in the U.S. and globally, and it is the exclusive manufacturer of these licensed products [4]. - Aquestive is advancing a late-stage proprietary product candidate for treating severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel for dermatology conditions [4]. Upcoming Events - The management team will hold a fireside chat on December 4, 2025, focusing on the product candidate Anaphylm™ (dibutepinephrine) sublingual film, discussing regulatory progress and commercial readiness [2]. - Investor meetings will also be hosted on the same day, providing opportunities for direct engagement with the management team [2]. Communication and Accessibility - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [3].

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for various cancers [3] - The company will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, with a presentation by CEO Mark Erlander [1][2] Company Overview - Cardiff Oncology is leveraging PLK1 inhibition, a validated oncology drug target, to create therapies for cancers such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer [3] - The lead asset, onvansertib, is being evaluated in combination with standard of care therapeutics to address treatment resistance and enhance clinical benefits [3]

Offer aims to leverage the brand for verified AI data licensing, verifiable and accurate financial news, and anchor a new global digital assets news organization.New York, NY, Nov. 24, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital (Nasdaq: ATON), a specialized digital asset technology company focused on the Telegram ecosystem, today announced that it has submitted a Letter of Intent (LOI) to acquire a 51% controlling interest in Forbes Media Holdings (FMH). The proposed acquisition is part of AlphaTON’s broader ...

Core Insights - Tilray Brands, Inc. has launched Good Supply vape products in Québec, marking a significant development in the legal cannabis vaping market in the province [1][2] - The introduction of these products is in full compliance with provincial regulations, ensuring that adult consumers have access to quality and regulated cannabis products [2] Product Details - Good Supply is offering 1 g 510-thread cartridges in two popular strains: Pineapple Express (Hybrid) and Blue Dream (Sativa) [1][2] - The cartridges are compatible with standard 510 batteries and can be purchased both in-store and online [1] - Pineapple Express features dominant terpenes myrcene, humulene, and linalool, while Blue Dream includes myrcene, linalool, and humulene [2] Brand Overview - Good Supply is recognized as one of Canada's leading cannabis brands, known for its top-selling flower, pre-rolls, vapes, and concentrates [3] - The brand focuses on delivering consistent quality at affordable prices, rooted in classic cannabis strains [3] Company Background - Tilray Brands, Inc. operates globally in the cannabis, beverage, and wellness industries, with a mission to be a leading premium lifestyle company [5] - The company supports over 40 brands across more than 20 countries, offering a wide range of cannabis products, hemp-based foods, and craft beverages [5][6]

NEW YORK and WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida. Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday, December 2, 2025 at 2:35 p.m. ET and will host ...

Core Insights - Abaxx Technologies Inc. has been included in the MSCI Canada Small Cap Index, effective November 24, 2025, marking a significant milestone for the company [1][3][11] - The MSCI Canada Small Cap Index represents approximately 14% of the free float-adjusted market capitalization in Canada, serving as a widely referenced benchmark in the financial industry [2] Company Overview - Abaxx Technologies is focused on building advanced market infrastructure and technology aimed at addressing major societal challenges, including the energy transition [4][6] - The company is the majority shareholder of Abaxx Singapore Pte. Ltd., which owns the Abaxx Commodity Exchange and Clearinghouse, and operates subsidiaries such as Abaxx Spot Pte. Ltd. and Adaptive Infrastructure [5][6] Business Developments - The company is generating revenue through its exchange, which features the only physically-backed LNG forward curves trading globally, and is launching a Digital Title pilot program involving tokenized gold and other assets [3][6] - Abaxx Exchange provides critical market infrastructure for a low-carbon economy, offering centrally-cleared, physically-deliverable futures contracts in various commodities [6][8] Innovations and Services - Abaxx Spot modernizes physical gold trading with a physically-backed gold pool in Singapore, facilitating secure electronic transactions and supporting physical delivery for gold futures contracts [7] - Adaptive Infrastructure addresses gaps in post-trade infrastructure by offering custodial services across environmental markets and digital title assets, enhancing reliability and reducing risk [8]

Core Viewpoint - Aldebaran Resources Inc. has filed an updated Technical Report and Preliminary Economic Assessment for the Altar copper-gold project, indicating a strong economic outlook for the project with significant production potential and attractive financial metrics [1][3]. Group 1: Project Details - The Altar Preliminary Economic Assessment (PEA) has an effective date of September 1, 2025, and was prepared by SRK Consulting Inc. with Knight Piesold as a subcontractor [1]. - The PEA indicates a base case scenario with a Net Present Value (NPV) of US$2 billion and an Internal Rate of Return (IRR) of 20.5%, highlighting the project's long-term viability and profitability [3]. - Aldebaran holds an 80% interest in the Altar project, which is located in San Juan Province, Argentina, and is part of a cluster of world-class porphyry copper deposits [6]. Group 2: Joint Venture Update - Nuton Holdings Ltd., a venture of Rio Tinto, has terminated its option to joint venture agreement to acquire a 20% interest in the Altar project, citing a shift in focus to later-stage projects [2]. - Despite the termination, there remains the potential for a licensing agreement between Nuton and Aldebaran to utilize Nuton Technology at the Altar project [2]. Group 3: Management Commentary - The CEO of Aldebaran expressed confidence in the Altar project, emphasizing its significance for both the company and Argentina, and acknowledged Nuton's participation while understanding their strategic shift [3].